On November 18, 2025, major financial media reported that Eli Lilly's weight-loss drug Zepbound is on track to become the world's top-selling drug, fueling optimism about the company's growth prospects. This development has brought Eli Lilly close to a $1 trillion market capitalization, underscoring the company's leadership in the pharmaceutical sector. While no specific price movement data is available for November 18, 2025, the news coverage suggests strong investor interest and positive sentiment driven by Zepbound's commercial potential. No major negative news or earnings surprises were reported, and the broader market context was relatively subdued.